Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 garetosmab versus placebo in adults with fibrodysplasia ossificans progressiva
NL-OMON53784Phase 3Not yet recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of garetosmab in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Number of new heterotopic ossification lesions at week 56 and Incidence and severity of adverse events of special interest through week 56. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
garetosmab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NL-OMON53784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53784.